Want to join the conversation?
$ESRX 2Q15 Call: With respect to formulary management, we provide flexible offerings that achieve industry-leading drug trend. Specialty drugs are expected to come for half of the total drug spends by 2018 and this is an opportunity & we are focused on investing in.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.